Tradename | Company | Number | Date | Products |
---|---|---|---|---|
REVLIMID | Bristol Myers Squibb | N-021880 RX | 2005-12-27 | 6 products, RLD |
Expiration | Code | ||
---|---|---|---|
LENALIDOMIDE, REVLIMID, BRISTOL MYERS SQUIBB | |||
2026-05-28 | ODE-241, ODE-245 | ||
2024-02-22 | ODE-131 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 141 | 274 | 103 | 12 | 40 | 499 |
Myelodysplastic syndromes | D009190 | — | D46 | 20 | 35 | 3 | 1 | 10 | 64 |
Follicular lymphoma | D008224 | — | C82 | 32 | 35 | 9 | 1 | 3 | 62 |
T-cell lymphoma peripheral | D016411 | — | — | 9 | 10 | — | 1 | — | 16 |
B-cell lymphoma | D016393 | — | — | 6 | 8 | 1 | 1 | — | 11 |
T-cell lymphoma | D016399 | — | — | 3 | 3 | — | 1 | — | 6 |
Hematologic neoplasms | D019337 | — | — | 1 | 3 | — | 1 | — | 4 |
Healthy volunteers/patients | — | — | — | 2 | — | — | 1 | — | 3 |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | 1 | — | 3 |
Pneumococcal pneumonia | D011018 | EFO_1001474 | J13 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 39 | 52 | 3 | — | 2 | 80 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 33 | 47 | 9 | — | 6 | 76 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 30 | 33 | 4 | — | 4 | 59 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 21 | 25 | 3 | — | 4 | 44 |
Lymphoma | D008223 | — | C85.9 | 16 | 27 | 4 | — | 2 | 38 |
Myeloid leukemia acute | D015470 | — | C92.0 | 20 | 17 | 1 | — | 3 | 37 |
Neoplasms | D009369 | — | C80 | 20 | 10 | 1 | — | — | 25 |
Plasma cell neoplasms | D054219 | — | — | 7 | 14 | 1 | — | 2 | 19 |
Smoldering multiple myeloma | D000075122 | — | — | 3 | 9 | 2 | — | — | 13 |
Prostatic neoplasms | D011471 | — | C61 | 5 | 7 | 1 | — | — | 10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 14 | 11 | — | — | — | 19 |
Leukemia | D007938 | — | C95 | 6 | 15 | — | — | 1 | 19 |
Hodgkin disease | D006689 | — | C81 | 13 | 10 | — | — | — | 18 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 8 | 8 | — | — | — | 13 |
Burkitt lymphoma | D002051 | — | C83.7 | 11 | 6 | — | — | — | 12 |
Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 8 | 7 | — | — | — | 10 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 7 | 4 | — | — | — | 9 |
Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 6 | 4 | — | — | — | 9 |
Plasma cell leukemia | D007952 | — | C90.1 | 3 | 5 | — | — | 1 | 8 |
Intraocular lymphoma | D064090 | — | — | 5 | 4 | — | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuroblastoma | D009447 | EFO_0000621 | — | 3 | — | — | — | — | 3 |
Colonic neoplasms | D003110 | — | C18 | 2 | — | — | — | — | 2 |
Rectal neoplasms | D012004 | — | — | 2 | — | — | — | — | 2 |
Disease | D004194 | EFO_0000408 | R69 | 2 | — | — | — | — | 2 |
Promyelocytic leukemia acute | D015473 | — | C92.4 | 2 | — | — | — | — | 2 |
Urethral neoplasms | D014523 | EFO_0003846 | — | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 1 | — | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
Tongue neoplasms | D014062 | EFO_0003871 | C02.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Residual neoplasm | D018365 | — | — | — | — | — | — | 1 | 1 |
Patient compliance | D010349 | — | — | — | — | — | — | 1 | 1 |
Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | — | — | — | — | 1 | 1 |
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
Personal satisfaction | D010549 | — | — | — | — | — | — | 1 | 1 |
Patient preference | D057240 | — | — | — | — | — | — | 1 | 1 |
Progression-free survival | D000077982 | — | — | — | — | — | — | 1 | 1 |
Dermatomyositis | D003882 | EFO_0000398 | M33 | — | — | — | — | 1 | 1 |
Oral ulcer | D019226 | HP_0000155 | — | — | — | — | — | 1 | 1 |
Drug common name | Lenalidomide |
INN | lenalidomide |
Description | Lenalidomide is a dicarboximide that consists of 1-oxoisoindoline bearing an amino substituent at position 4 and a 2,6-dioxopiperidin-3-yl group at position 2. It inhibits the secretion of TNF-alpha and has a role as an angiogenesis inhibitor, an antineoplastic agent and an immunomodulator. It is a member of isoindoles, a dicarboximide, a member of piperidones and an aromatic amine. Lenalidomide is a thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. |
Classification | Small molecule |
Drug class | thalidomide derivatives; narcotic agonists/antagonists (normorphine type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O |
PDB | — |
CAS-ID | 191732-72-6 |
RxCUI | — |
ChEMBL ID | CHEMBL848 |
ChEBI ID | 63791 |
PubChem CID | 216326 |
DrugBank | DB00480 |
UNII ID | F0P408N6V4 (ChemIDplus, GSRS) |